ArticleResearch in pharmaceutical sciences2026
Sitagliptin protects against bile duct ligation-induced cholemic nephropathy in male rats through modulation of inflammation, sestrin2, and the Nrf2/SOD pathway.
Article in Research in pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Cholestasis or bile duct ligation (BDL) could develop cirrhosis and may lead to other organ dysfunction, including the kidneys, which is called cholemic nephropathy (CN). Hyperbilirubinemia, bile acid accumulation, renal hypoperfusion, oxidative stress, and inflammation are implicated in the pathogenesis of CN. Sitagliptin is an oral antihyperglycemic drug with anti-inflammatory and anti-oxidative effects. Its effects on CN were unknown. Experimental approach: The BDL-induced CN model was performed in 35 male Wistar rats (200-250 g), which were divided into five groups (n = 7) as follows: sham group receiving distilled water as vehicle (sham + Veh), BDL group receiving vehicle (BDL + Veh), and BDL groups receiving sitagliptin at the doses of 10, 50, or 100 mg/kg/day by gavage for 14 days named BDL + Sit 10, BDL + Sit 50, and BDL + Sit 100, respectively. Aspartate transferase, alkaline phosphatase, total bilirubin (T-Bil), renal function biomarkers, creatinine (Cr) clearance, redox system status, TNF-α, and renal histopathology were evaluated. Findings/Results: BDL increased serum liver enzymes, T-Bil, Cr, urea, urine Cr, albumin to Cr ratio, and decreased Cr clearance. Also, BDL elevated renal sestrin2, malondialdehyde, TNF-α, renal index, and kidney tissue injury score, while reducing superoxide dismutase (SOD) activity, total antioxidant capacity, and nuclear factor erythroid 2-related factor 2 (Nrf2). Sitagliptin, especially at the low dose, reversed these effects. Conclusion and implications: Sitagliptin improved renal injury and function
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.